Investor Presentaiton

Expanding opportunity Significant capital needs Innovative funding Facilitating M&A Differentiated sourcing Proprietary sourcing provides competitive advantage Source of deals (1) Network of deep relationships 30% 59% 18% 28% 52% 13% Pharma M&A Bilateral ROYALTY PHARMA Limited process(2) Auction Track record of "win-win" outcomes Scale advantages Strong record of value-enhancing acquisitions ROYALTY PHARMA Majority of Royalty Pharma transactions negotiated on a bilateral basis (1) Includes all Royalty Pharma transactions announced from January 2016 to January 2022; analysis of Schedule 14D-9s for pharma M&A transactions and includes biotech acquisitions greater than $1 billion in value (46 in total). Percentages are based on number of transactions. (2) Limited process is three or fewer parties involved in process. 44

View entire presentation